clinical trial · NCT03108066
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·phase2·completed·n = 4
VHL Gene MutationVHLVHL SyndromeVHL Gene InactivationVon HippelVon Hippel-Lindau DiseaseVon Hippel's DiseaseVon Hippel-Lindau Syndrome, Modifiers ofMK-3795
brief summary
The primary objective of this study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL participants treated with MK-3795.
started
Apr 24, 2017
primary completion
Aug 30, 2023
completion
Sep 27, 2023
last updated
Sep 24, 2024
detailed description
This open-label Phase 2 study will evaluate the efficacy, safety, PK, and PD of MK-3795 in participants with VHL disease who have at least 1 measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). MK-3795 will be administered orally and treatment will be continuous. Changes in VHL disease-associated non-ccRCC tumors will also be evaluated.
official title
An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol